Annual report pursuant to Section 13 and 15(d)

5. Acquisitions (Details Narrative)

v3.20.4
5. Acquisitions (Details Narrative) - USD ($)
2 Months Ended 7 Months Ended 12 Months Ended
Mar. 01, 2019
Jul. 19, 2019
Dec. 31, 2020
Dec. 31, 2019
Issuance of common stock in connection with purchase of in-process research and development, value       $ 3,031,226
Research and development expense     $ 1,731,406 4,889,340
General and administrative expense     $ 3,400,071 4,731,176
XCART Technology [Member]        
Issuance of common stock in connection with purchase of in-process research and development, value   $ 4,100,000    
Research and development expense       3,000,000
General and administrative expense       $ 1,100,000
Hesperix [Member] | Share Purchase Agreement [Member]        
Issuance of common stock in connection with purchase of in-process research and development, shares 406,246      
OPKO Pharmaceuticals, Inc. [Member] | Share Purchase Agreement [Member]        
Issuance of common stock in connection with purchase of in-process research and development, shares   164,062    
Scripps Research [Member] | Share Purchase Agreement [Member]        
Issuance of common stock in connection with purchase of in-process research and development, shares   54,687